Hutchison SK, Harrison C, Stepto N, Meyer C, Teede HJ
Reddys Laboratories has launched Obeda, semaglutide injection following approval from the Drugs Controller General of India (DCGI), marking its entry into the fast-growing GLP-1 receptor agonist therapy segment
Its role is to: Enhance insulin secretion when blood sugar rises Reduce glucagon secretion , lowering blood glucose production Slow stomach emptying , which promotes satiety Reduce appetite , leading to weight loss Since natural GLP-1 breaks down quickly, drug companies created synthetic GLP-1 receptor agonists (like semaglutide in Ozempic/Wegovy) that stay active longer
Lower concentrations would push injection volumes uncomfortably high
Common examples include: Ozempic: FDA-approved for type 2 diabetes but sometimes prescribed off-label for weight loss
Rev Bras Zootec